MRI-derived extracellular volume as a biomarker of cancer therapy cardiotoxicity: systematic review and meta-analysis.
Gianluca FolcoCaterina Beatrice MontiMoreno ZanardoFrancesco SillettaDavide CapraFrancesco SecchiFrancesco SardanelliPublished in: European radiology (2023)
• Cardiotoxicity is a common adverse effect of cancer therapy; therefore, its prompt detection could improve patient outcomes. • Pooled MRI-derived myocardial extracellular volume was higher in patients who underwent cardiotoxic cancer therapy than in those who did not (28.44% versus 25.23%, p = .003). • MRI-derived myocardial extracellular volume represents a potential early biomarker of cancer therapy cardiotoxicity.
Keyphrases
- cancer therapy
- drug delivery
- contrast enhanced
- magnetic resonance imaging
- end stage renal disease
- diffusion weighted imaging
- left ventricular
- ejection fraction
- newly diagnosed
- chronic kidney disease
- magnetic resonance
- peritoneal dialysis
- prognostic factors
- emergency department
- clinical trial
- heart failure
- risk assessment
- human health
- atrial fibrillation
- label free